TAP Initiates Phase III Studies for Investigational New Gastroenterology Product
Posted on: Tuesday, 30 August 2005, 03:01 CDT
LAKE FOREST, Ill., Aug. 30 /PRNewswire/ -- TAP Pharmaceutical Products Inc. today announced that it is initiating Phase III studies for an investigational new product, TAK-390MR, for the treatment of acid-related disorders. In addition to the development of TAK-390MR, TAP will be focusing development efforts on other investigational products for gastroenterological conditions.
Licensed from Takeda Pharmaceutical Company Limited, TAK-390MR employs a new modified release (MR) technology on an enantiomer of lansoprazole.
"Phase I clinical trial data have shown that TAK-390MR may have the potential to bring additional benefits to patients who suffer from acid- related diseases," said Francois-Xavier Frapaise, MD, vice president of research and development for TAP. "We are enthusiastic to initiate a comprehensive Phase III clinical program involving more than 5,000 patients."
TAP has been a vital part of the gastroenterological community for over ten years, supporting important research and education for patients and physicians about acid-related disorders.
"TAP is committed to our mission of bringing important medicines to patients who need them by identifying and developing high-potential products," said Alan MacKenzie, president of TAP. "We are excited about the potential of TAK-390MR and advancing our gastroenterology franchise."
About TAP Pharmaceutical Products Inc.
TAP Pharmaceutical Products Inc., located in Lake Forest, Ill., is a joint venture between Abbott, headquartered in Abbott Park, Ill., and Takeda Pharmaceutical Company Limited, of Osaka, Japan. TAP markets Prevacid(R) (lansoprazole) and Lupron Depot(R) (leuprolide acetate for depot suspension). For more information about TAP Pharmaceutical Products Inc., and its products, visit the company's Web site at http://www.tap.com/ .
Contact: Media Katherine Stueland (847) 582-6100 Financial Community - Abbott John Thomas (847) 938-2655 Financial Community - Takeda Seizo Masuda +81-6-6204-2060
TAP Pharmaceutical Products Inc.
CONTACT: Media, Katherine Stueland for TAP Pharmaceutical Products Inc.,+1-847-582-6100, or Financial Community - Abbott, John Thomas,+1-847-938-2655, or Financial Community - Takeda, Seizo Masuda,+81-6-6204-2060
Web site: http://www.tap.com/
Source: PRNewswire
Related Articles
- C O R R E C T I O N -- Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results
- MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results
- Jazz Pharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
- Molecular Insight Pharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
- Researchers Tapped Thomson Reuters Community of Cancer Patients for Studies To Be Reported at American Society of Clinical Oncology Conference
- TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients With Erosive Esophagitis
- ExpoTV Taps Into Its Community of Consumer Enthusiasts for Coverage of 2008 New York Auto Show
- Molecular Insight Pharmaceuticals, Inc. Announces Second Quarter 2007 Financial Results
- Nymox Pharmaceutical to Present at the Noble Financial Small Cap Conference
- CORRECTING and REPLACING Optical Communication Products Schedules Release of First Quarter 2005 Financial Results and Conference Call
 |
 |
User Comments (0)
RSS Feeds